Abstract
Islet-Brain (IB) proteins [also called JNK-interacting proteins (JIPs)] are scaffold proteins that are mainly expressed in the pancreatic islets and in the brain. Functionally, the IB family is composed of IB1, IB2, IB3, and IB4 each with distinct splice variants. The IB family of proteins regulates several mitogen-activated protein kinase (MAPK) pathways by tethering their components and modifying the spectrum of substrates targeted by the MAPKs. The expression of these proteins is developmentally regulated, indicating that they play important functions during brain formation. While it is currently unclear what the precise physiological functions of the IB proteins are, there are indications that they participate in subcellular targeting of signalling proteins and modulate cell survival. Synthetic derivatives of these proteins can efficiently counteract apoptotic signalling in cells and tissues and represent therefore promising protective agents against traumatic insults, including stroke and hypoxia. This review will focus on the molecular functions of the IB proteins and their potential implications in the development of several human pathologies.
Keywords: neurodegeneration, alzeihmers disease, apoptosis, mapk, diabetes
Current Neurovascular Research
Title: Islet-Brain (IB)/JNK-Interacting Proteins (JIPs): Future Targets for the Treatment of Neurodegenerative Diseases?
Volume: 1 Issue: 2
Author(s): Nathalie Moulin and Christian Widmann
Affiliation:
Keywords: neurodegeneration, alzeihmers disease, apoptosis, mapk, diabetes
Abstract: Islet-Brain (IB) proteins [also called JNK-interacting proteins (JIPs)] are scaffold proteins that are mainly expressed in the pancreatic islets and in the brain. Functionally, the IB family is composed of IB1, IB2, IB3, and IB4 each with distinct splice variants. The IB family of proteins regulates several mitogen-activated protein kinase (MAPK) pathways by tethering their components and modifying the spectrum of substrates targeted by the MAPKs. The expression of these proteins is developmentally regulated, indicating that they play important functions during brain formation. While it is currently unclear what the precise physiological functions of the IB proteins are, there are indications that they participate in subcellular targeting of signalling proteins and modulate cell survival. Synthetic derivatives of these proteins can efficiently counteract apoptotic signalling in cells and tissues and represent therefore promising protective agents against traumatic insults, including stroke and hypoxia. This review will focus on the molecular functions of the IB proteins and their potential implications in the development of several human pathologies.
Export Options
About this article
Cite this article as:
Moulin Nathalie and Widmann Christian, Islet-Brain (IB)/JNK-Interacting Proteins (JIPs): Future Targets for the Treatment of Neurodegenerative Diseases?, Current Neurovascular Research 2004; 1 (2) . https://dx.doi.org/10.2174/1567202043480161
DOI https://dx.doi.org/10.2174/1567202043480161 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Murine Models of Vpr-Mediated Pathogenesis
Current HIV Research Erythropoietin: Cytoprotection in Vascular and Neuronal Cells
Current Drug Targets - Cardiovascular & Hematological Disorders Targeting Myc in Pediatric Malignancies of the Central and Peripheral Nervous System
Current Cancer Drug Targets Key miRNAs in Modulating Aging and Longevity: A Focus on Signaling Pathways and Cellular Targets
Current Molecular Pharmacology c-Myc and Downstream Targets in the Pathogenesis and Treatment of Cancer
Recent Patents on Anti-Cancer Drug Discovery Conformational Changes of Prion Protein and Nucleic Acid Arising from their Interaction and Relation of the Altered Structures in Causing Prion Disease
Mini-Reviews in Medicinal Chemistry Recent Advances in the Development of Selective Ligands for the Cannabinoid CB2 Receptor
Current Topics in Medicinal Chemistry Cell Death in Mammalian Development
Current Pharmaceutical Design Loss of the Tumor Suppressor HACE1 Contributes to Cancer Progression
Current Drug Targets Nogo Receptor Interacts with Brain APP and Aβ to Reduce Pathologic Changes in Alzheimers Transgenic Mice
Current Alzheimer Research Crosstalk of Long Non-coding RNAs and EMT: Searching the Missing Pieces of an Incomplete Puzzle for Lung Cancer Therapy
Current Cancer Drug Targets FoxO Proteins: Regulation and Molecular Targets in Liver Cancer
Current Medicinal Chemistry Restoring p53 Function in Cancer: Novel Therapeutic Approaches for Applying the Brakes to Tumorigenesis
Recent Patents on Anti-Cancer Drug Discovery An Image-Based Biosensor Assay Strategy to Screen for Modulators of the microRNA 21 Biogenesis Pathway
Combinatorial Chemistry & High Throughput Screening Regulation of Gait and Balance: The Underappreciated Role of Neuronal Nicotinic Receptor Agonists
Current Pharmaceutical Design The Role, Significance, and Association of MicroRNA-10a/b in Physiology of Cancer
MicroRNA From Na+/K+-ATPase and Cardiac Glycosides to Cytotoxicity and Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in Phenanthroindolizidine and Phenanthroquinolizidine Derivatives with Anticancer Activities
Anti-Cancer Agents in Medicinal Chemistry Tumor Homing Peptides as Molecular Probes for Cancer Therapeutics, Diagnostics and Theranostics
Current Medicinal Chemistry Mangrove Plants as a Source of Bioactive Compounds: A Review
The Natural Products Journal